-
2024-516993-31-00
5
2026-05-11
Renal Cell Carcinoma
-
2025-522963-14-00
1
2026-05-09
Μuscle-invasive bladder cancer (MIBC) patients, eligible for neobladde
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2025-523123-22-00
5
2026-05-07
Chronic Kidney Disease
-
2025-523552-31-00
5
2026-05-07
Systemic Lupus Erythematosus
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2025-522705-37-00
4
2026-04-21
HIDRADENITIS SUPPURATIVA
-
2024-520444-42-00
5
2026-04-15
Overweight or obesity, and knee osteoarthritis
-
2024-520445-23-00
5
2026-04-15
Overweight or obesity, and knee osteoarthritis
-
2024-513174-22-00
4
2026-04-14
Atrophic Age-related Macular Degeneration (AMD)
-
2025-522544-40-00
5
2026-03-27
Hereditary transthyretin-mediated amyloidosis with polyneuropathy
-
2023-504957-11-00
5
2026-03-24
Metastatic castration resistant prostate cancer
-
2025-521036-11-00
5
2026-03-23
Immune system disseases
-
2025-521621-33-00
6
2026-03-16
Metastatic Melanoma
-
2025-521416-19-00
4
2026-03-12
Recurrence of Clostridioides difficile Infection
-
2025-522232-13-00
4
2026-03-06
Sepsis-associated acute kidney injury (AKI)
-
2025-521284-12-00
5
2026-03-05
Non-small cell lung cancer
-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-522151-26-00
5
2026-02-06
Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growt